Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009926 | 0.77 | FLT1 (0.30) | — | |
| SCHEMBL6026196 | 0.75 | RAPGEF4 (0.31) | — | |
| SCHEMBL29385092 | 0.75 | RAPGEF4 (0.31) | — | |
| SCHEMBL286168 | 0.75 | RAPGEF4 (0.31) | — | |
| SCHEMBL23364165 | 0.74 | MMP1 (0.31) | — | |
| SCHEMBL2112663 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2085147 | 0.71 | — | — | |
| SCHEMBL30401259 | 0.71 | — | — | |
| SCHEMBL25202347 | 0.71 | — | — | |
| SCHEMBL5257885 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429663-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| CN-102333781-A | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
| US-5250527-A | Enzyme inhibitors; administering to reduce gastric acid secretion | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-10-05 | — | — | US | disclosed |
| CN-1013445-B | PROCESS FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS | SMITH KLINE FRENCH LAB (GB) | 1991-08-07 | — | — | CN | disclosed |
| EP-0184322-B1 | BENZIMIDAZOLES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| EP-0184322-A1 | Benzimidazoles | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-06-11 | — | — | EP | disclosed |
| CN-85108133-A | Compounds process for production thereof | — | 1986-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 725/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.